Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer.
Choline
MRI
PET
PSMA
Prostate cancer
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
22
10
2019
accepted:
21
12
2019
pubmed:
8
1
2020
medline:
27
5
2021
entrez:
8
1
2020
Statut:
ppublish
Résumé
Whole-body positron emission tomography/magnetic resonance imaging (wbPET/MRI) is a promising diagnostic tool of recurrent prostate cancer (PC), but its role in primary staging of high-risk PC (hrPC) is not well defined. Thus, the aim was to compare the diagnostic accuracy for T-staging of PET-blinded reading (PBR) and PET/MRI. In this prospective study, hrPC patients scheduled to radical prostatectomy (RPx) with extended lymphadenectomy (eLND) were staged with wbPET/MRI and either Thirty-four patients underwent wbPET/MRI of MpMRI is the primary modality for T-staging in hrPC as PET underestimated T-stage in direct comparison to final pathology. In this selected study, cohort MRI shows no inferiority compared to wbPET/MRI considering N-staging.
Identifiants
pubmed: 31907632
doi: 10.1007/s00345-019-03066-1
pii: 10.1007/s00345-019-03066-1
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2513-2521Références
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J (2012) Jemal A (2015) Global cancer statistics. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262
doi: 10.3322/caac.21262
Siegel RL, Miller KD (2016) Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332
doi: 10.3322/caac.21332
pubmed: 26742998
pmcid: 26742998
Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990–2007. World J Urol 26(3):211–218. https://doi.org/10.1007/s00345-008-0250-7
doi: 10.1007/s00345-008-0250-7
pubmed: 18369637
pmcid: 2948572
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974
doi: 10.1001/jama.280.11.969
Oesterling JE (1993) Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin N Am 20(4):705–711
Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6):1251–1265. https://doi.org/10.1016/j.eururo.2009.03.012
doi: 10.1016/j.eururo.2009.03.012
pubmed: 19297079
Checcucci E, Amparore D, De Luca S, Autorino R, Fiori C, Porpiglia F (2019) Precision prostate cancer surgery: an overview of new technologies and techniques. Minerva Urol Nefrol 71(5):487–501. https://doi.org/10.23736/s0393-2249.19.03365-4
doi: 10.23736/s0393-2249.19.03365-4
pubmed: 30700084
Jazayeri SB, Weissman B, Samadi DB (2018) Outcomes following robotic-assisted laparoscopic prostatectomy: Pentafecta and Trifecta achievements. Minerva Urol Nefrol 70(1):66–73. https://doi.org/10.23736/s0393-2249.17.02909-5
doi: 10.23736/s0393-2249.17.02909-5
pubmed: 28882030
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003
doi: 10.1016/j.eururo.2016.08.003
pubmed: 27568654
Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395. https://doi.org/10.1016/j.crad.2007.05.022
doi: 10.1016/j.crad.2007.05.022
pubmed: 18325358
Albisinni S, Aoun F, Marcelis Q, Jungels C, Al-Hajj Obeid W, Zanaty M, Tubaro A, Roumeguere T, De Nunzio C (2018) Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review. Minerva Urol Nefrol 70(4):347–360. https://doi.org/10.23736/s0393-2249.18.03059-x
doi: 10.23736/s0393-2249.18.03059-x
pubmed: 29388415
Rosenkrantz AB, Friedman K, Chandarana H, Melsaether A, Moy L, Ding YS, Jhaveri K, Beltran L, Jain R (2016) Current status of hybrid PET/MRI in oncologic imaging. AJR Am J Roentgenol 206(1):162–172. https://doi.org/10.2214/AJR.15.14968
doi: 10.2214/AJR.15.14968
pubmed: 26491894
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(1):11–20. https://doi.org/10.1007/s00259-013-2525-5
doi: 10.1007/s00259-013-2525-5
pubmed: 24072344
Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, Afshar-Oromieh A, Kopka K, Debus J, Haberkorn U, Kratochwil C (2016) Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 43(8):1400–1406. https://doi.org/10.1007/s00259-016-3346-0
doi: 10.1007/s00259-016-3346-0
pubmed: 26971788
pmcid: 4906063
Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougere C (2017) Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44(1):92–101. https://doi.org/10.1007/s00259-016-3490-6
doi: 10.1007/s00259-016-3490-6
pubmed: 27557844
Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G (2018) The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol 70(5):462–478. https://doi.org/10.23736/s0393-2249.18.03081-3
doi: 10.23736/s0393-2249.18.03081-3
pubmed: 29664244
Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048. https://doi.org/10.1016/j.eururo.2012.09.039
doi: 10.1016/j.eururo.2012.09.039
pubmed: 23036576
Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69(1):16–40. https://doi.org/10.1016/j.eururo.2015.08.052
doi: 10.1016/j.eururo.2015.08.052
pubmed: 26427566
Sobin LH, Gospodariwicz M, Wittekind C (2009) TNM classification of malignant tumors UICC International Union Against Cancer, vol 7. Wiley-Blackwell, New York, pp 243–248
Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T (2016) Simultaneous (68)Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 70(5):829–836. https://doi.org/10.1016/j.eururo.2015.12.053
doi: 10.1016/j.eururo.2015.12.053
pubmed: 26795686
Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, Schafers M, Bogemann M (2016) Correlation of intraprostatic tumor extent with (6)(8)Ga-PSMA distribution in patients with prostate cancer. J Nucl Med 57(4):563–567. https://doi.org/10.2967/jnumed.115.169243
doi: 10.2967/jnumed.115.169243
pubmed: 26769858
Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, Bartenstein P, Kirchner T, Gildehaus FJ, Gratzke C, Faber C (2016)
doi: 10.2967/jnumed.116.172627
pubmed: 27261520
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM (2013) PET imaging with a [
doi: 10.1007/s00259-012-2298-2
pubmed: 23179945
Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, Wood D, Johnson T, Shah RB, Meyer C (2009) Detection of aggressive primary prostate cancer with
doi: 10.2967/jnumed.109.063396
pubmed: 19759109
pmcid: 2837847
Park H, Meyer CR, Wood D, Khan A, Shah R, Hussain H, Siddiqui J, Seo J, Chenevert T, Piert M (2010) Validation of automatic target volume definition as demonstrated for
doi: 10.1016/j.acra.2010.01.003
pubmed: 20188602
pmcid: 2854219
Budaus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C (2016) Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69(3):393–396. https://doi.org/10.1016/j.eururo.2015.06.010
doi: 10.1016/j.eururo.2015.06.010
pubmed: 26116958
Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M (2016) Value of
doi: 10.2967/jnumed.116.173492
pubmed: 27261524
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kubler H, Beer AJ, Schwaiger M, Eiber M (2016) Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195(5):1436–1443. https://doi.org/10.1016/j.juro.2015.12.025
doi: 10.1016/j.juro.2015.12.025
pubmed: 26682756
Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP (2016) (68)Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 70(4):553–557. https://doi.org/10.1016/j.eururo.2015.12.051
doi: 10.1016/j.eururo.2015.12.051
pubmed: 26810345
van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD (2017) Prospective evaluation of
doi: 10.1111/bju.13540
pubmed: 27207581
Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, Langsteger W, Janetschek G (2006) Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [
doi: 10.1016/j.juro.2006.07.037
pubmed: 17070241
Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell PJ, Nelson C, Chung E, Wood G, Malone G, Wood S, Heathcote P (2016) Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer. J Urol 196(4):1261–1267. https://doi.org/10.1016/j.juro.2016.02.3000
doi: 10.1016/j.juro.2016.02.3000
pubmed: 27220897
Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, Krauss T, Mix M, Schiller F, Wetterauer U, Werner M, Langer M, Bock M, Meyer PT, Grosu AL (2017) Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics 7(1):228–237. https://doi.org/10.7150/thno.16638
doi: 10.7150/thno.16638
pubmed: 28042330
pmcid: 5196899